CD28 and myeloid sarcoma: (2017) found that production of Th17-cytokines IL-17, IL-22, and GM-CSF by anti-CD3/CD28-activated PBMCs is higher in relapsing-remitting MS patients with fatigue (n=15) compared to MS patients without fatigue (n=15) (51).